Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering
Apr
23
2024
On demand

Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Viral-based gene transfer introduces both safety risks and logistical challenges to scaling cell therapies, including high costs, long manufacturing times, and supply chain instability. Many developers are therefore seeking alternative approaches to control manufacturing costs and get therapies to market faster.

Non-viral gene delivery systems, such as the TcBuster™ transposon system, offer a highly cost-effective alternative to lentiviral vectors. The ability to safely and stably integrate large DNA cargos at high efficiency makes non-viral gene delivery an exciting option for CAR-T and CAR-NK cell therapies stem cell-based therapy development.

The logistical benefits of non-viral genome engineering include shorter, simpler cell manufacturing processes and lower cost per patient. But how does it perform compared to lentivirus?

In this webinar, Miles Smith, Genome Engineering Product Manager at Bio-Techne will present data comparing the performance of non-viral and lentiviral-based gene delivery systems in primary human T cells, including cargo capacity, integration efficiency and safety profile, cell expansion, cell phenotype, and cytotoxicity.

Join this webinar for case studies showing how:

  • A non-viral system, TcBuster, outperforms lentivirus when inserting larger constructs into primary human T cells
  • T cells were modified by both systems and expanded to full confluency
  • Copy number and site integration analysis in T cells showed a lower potential for gene disruption
  • TcBuster-modified T cells contained a significantly higher percentage of stem cell memory T cells
  • Both gene delivery systems were similarly efficacious against CD19-expressing target cells
Miles Smith
Miles Smith
Product Manager at Bio-Techne Ltd

Miles Smith is a Cell and Gene Therapy Product Manager at Bio-Techne. In this role, Miles is responsible for the genome engineering portfolio, which includes the TcBusterTM transposon system. Miles joined Bio-Techne in 2023 to enable scientists and entrepreneurs with a non-viral approach to deliver next-generation cell therapies. He earned a PhD from the University of Minnesota in Molecular and Cellular Biology, focusing on gene therapies for lysosomal storage disorders. He also earned a BA in Biology from St. Olaf College.

SPEAKERS

Miles Smith
Miles Smith
Product Manager at Bio-Techne Ltd